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Abstract
(1) Objectives—To investigate whether urinary levels of macrophage migration inhibitory factor
(MIF) are elevated in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) patients with Hunner
lesions and also whether urine MIF is elevated in other forms of inflammatory cystitis.
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(2) Methods—Urine samples were assayed for MIF by ELISA. Urine samples from three female
groups were examined: IC/BPS patients without (N=55) and with Hunner lesions (N=43); NonIC/BPS patients (N=100; control group; no history of IC/BPS; cancer or recent bacterial cystitis).
Urine samples from three male groups were examined: patients with bacterial cystitis (N=50),
radiation cystitis (N=18) and non-cystitis patients (N = 119; control group; negative for bacterial
cystitis).
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(3) Results—Urine MIF (Mean MIF pg/ml ± SEM) was increased in female IC/BPS patients
with Hunner lesions (2159 ± 435.3) compared to IC/BPS patients without Hunner lesions (460
± 114.5) or non-IC/BPS patients (414 ± 47.6). Receiver-operating curve analyses showed that
urine MIF levels discriminated between the two IC groups (AUC = 72%; CI: 61–82%). Male
patients with bacterial and radiation cystitis had elevated urine MIF levels (2839 ± 757.1 and 4404
± 1548.1; respectively) compared to non-cystitis patients (681 ± 75.2).
(4) Conclusions—Urine MIF is elevated in IC/BPS patients with Hunner lesions and also in
patients with other bladder inflammatory and painful conditions. MIF also may serve as a
noninvasive biomarker to select IC/BPS patients more accurately for endoscopic evaluation and
possible anti-inflammatory treatment.

Introduction
Author Manuscript

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a debilitating condition with
between 3 and 8 million women and approximately 2 million men in the US having
symptoms 1,2. The condition has poorly defined etiology, variable histological findings and
no consistently effective treatments. Different clinical definitions have been proposed, with a
common theme of pain or discomfort perceived to arise from the bladder 3. These patients
are commonly subdivided into those with gross inflammatory disease (Hunner lesions) and
those without, the former often requiring more aggressive management.

Author Manuscript

Cytoscopy is necessary to identify Hunner lesions; however, this examination is not
mandated in the early evaluation of afflicted patients. A urine biomarker that identifies
IC/BPS patients in general and those with Hunner lesions in particular, would potentially
streamline diagnosis and direct the most appropriate therapeutic options without the need for
invasive procedures. Furthermore, such a marker might provide prognostic information and
pose a target for future interventions.
Macrophage migration inhibitory factor (MIF) is a soluble factor produced by Tlymphocytes with the ability to stop migration of macrophages and was one of the first
cytokines to be identified 4. Subsequently, MIF has been shown to be expressed in a variety
of immune and non-immune cells. Ample experimental evidence shows that MIF is a
regulator of immunity that appears to be active in generalized inflammatory events such as
sepsis and autoimmune diseases such as rheumatoid arthritis 5.
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MIF is constitutively expressed in human urothelial cells 6 and stored MIF pools in the
urothelium are released into the bladder lumen after bladder insults, as demonstrated by
various experimental rodent models of cystitis 7,8. Released MIF then binds to MIF
receptors on the bladder surface to mediate bladder inflammation and bladder pain 9–11.
Based on this experimental evidence, we hypothesized that urinary MIF levels would be
increased in patients with inflammatory and painful conditions of the bladder. Our primary
aim was to measure urine MIF levels in IC/BPS patients with and without Hunner lesions
and compare them to controls (non-IC/BPS individuals). In addition, we investigated
whether urine MIF may be a useful biomarker for IC/BPS patients with Hunner lesions. Our
secondary aim in this study was to extend previous findings 12 by examining a larger cohort
of adult patients with confirmed bacterial cystitis and comparing them to a non-Cystitis
Urology. Author manuscript; available in PMC 2019 June 01.
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group. In addition, we added a cohort of radiation cystitis patients, as a positive control
cohort for bladder inflammation.

Methods
Subject Populations
Urine samples were collected from the following groups of patients:
1.

Author Manuscript
2.

Author Manuscript
3.

Female Non-IC/BPS (Control group): No history of IC/BPS, cancer or recent (3
month) bacterial cystitis.
a.

Banked samples (N=92): Samples were obtained from participants in
the Kentucky Women Health Registry and were collected as part of
routine visits to healthcare providers and distributed by the
Biospecimens Core of the Kentucky Center for Clinical and
Translational Science, University of Kentucky. Procedures were
approved by the Institutional Review Board at the University of
Kentucky

b.

Collected samples (N=8): Obtained (after IRB approval and informed
consent) during routine visit to urologists’ clinics (Zucker School of
Medicine at Hofstra-Northwell).

Women with IC/BPS without Hunner lesions (IC/BPS-NH): IC/BPS was
diagnosed using the same criteria that are described in the American Urological
Association Guideline for Diagnosis and Treatment of IC/BPS. All subjects had
symptom duration > 1 year and were symptomatic at the time of urine collection
and underwent cystoscopy.
a.

Banked samples (N=14): Samples were obtained from existing samples
(University of Gothenburg; collected between 1994–1997).

b.

Collected Samples: Samples were collected (with IRB approval from
respective institutions) during office visits at:
i.

Zucker School of Medicine at Hofstra-Northwell (N=38)

ii.

University of Kentucky (N=3)
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Women with IC/BPS with Hunner lesions (IC/BPS-H): IC/BPS was diagnosed
using the same criteria that are described in the American Urological Association
Guideline for Diagnosis and Treatment of IC/BPS. All subject had symptom
duration > 1 year and were symptomatic at the time of urine collection and
underwent cystoscopy.
a.

Banked samples (N=26): Samples were obtained from existing samples
(University of Gothenburg; collected between 1994–1997).

b.

Collected Samples: Samples were collected (with IRB approval from
respective institutions) during office visits at:
i.

Zucker School of Medicine at Hofstra-Northwell (N=14)
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ii.

University of Kentucky (N=3)
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4.

Male Non-Cystitis (Control group; N=119): negative for bacterial cystitis; no
obvious urologic pathology on cystoscopic exam or any studies performed
(subjects gave informed consent of diagnostic procedures and urine specimens
were collected as part of the procedure; Lexington VAMC).

5.

Men with Bacterial Cystitis (N=50): confirmed by culture; no clinical signs of
pyelonephritis (patients gave informed consent of diagnostic procedures and
urine specimens were collected as part of the procedure; Lexington VAMC).

6.

Men with Radiation Cystitis (N=18): confirmed by clinical observation, history
and cystoscopy (patients gave informed consent and samples collected during
office visits; The Bay Pines VA Healthcare System).

Author Manuscript

Urine MIF assay and analyses
Upon receipt, all samples were centrifuged, pellet discarded, treated with protease inhibitors
(Thermo Scientific, 1%), aliquoted and stored at −80 °C until analysis. Samples were
assayed in duplicate for urine MIF levels using a commercially available ELISA kit (R&D;
DY289). Urine creatinine levels were measured using a commercially available kit (Enzo,
ADI-907-030).
The following parameters were obtained for each group: applicable demographics, age (at
time of urine collection); urine MIF levels (pg MIF/ml); urine MIF normalized to creatinine
(MIF pg/mg Creat). Values reported are mean ± standard error of the mean, SEM.

Author Manuscript

The study was designed so that an N = 50 in each group would result in 78% power for
analysis of variance to detect a significant difference (p = 0.05; medium effect size = .25) or
for individual group tests to have 80% power in detecting significant differences (p =0.05,
medium effect size = 0.5; 13). Statistical differences were determined using analysis of
variance followed by Tukey tests using R 14. Area under the curve (AUC) and Receiver
Operating Characteristic Curve (ROC) analyses were performed using the pROC package 15
for R.

Results
Patient Demographics

Author Manuscript

Table 1 shows the demographic characteristics for all groups studied. Most of the female
subjects (91%) identified themselves as White, while 4% identified themselves AfricanAmerican or Hispanic and 1% identified themselves as Asian. Most of the male subjects
(86%) identified themselves as White, while 11% and 1.6% identified themselves as
African-Americans or Hispanic, respectively. Patients without Hunner lesions were younger
(43 ± 1.9) than those in the non-IC/BPS (control) group (54 ± 1.2) while patients with
Hunner lesions were older (64 ± 2.0) than the other two subject groups and these differences
were statistically significant (Table 1). Male non-cystitis samples came from subjects with a
mean age of years, while patients with bacterial cystitis had a mean age of 67 ± 1.1 years
and patients with radiation cystitis had a mean age of 64 ± 0.7 years. Non-cystitis patients
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(63 ± 0.9) were younger than bacterial cystitis patients. Age of radiation cystitis patients was
not different from non-cystitis patients. (Table 1).
MIF levels in female patients: Non-IC/BPS (Control group), IC/BPS without Hunner lesions,
IC/BPS with Hunner lesions
Table 2A and Figure 1A; B summarize the findings on urinary MIF levels in Non-IC/BPS
female samples, and those from female IC/BPS patients with or without Hunner lesions.

Author Manuscript

Urine MIF concentrations (pg/ml) were not significantly different between IC/BPS patients
without Hunner lesions (IC/BPS-NH; mean= 460 ± 114.5; N = 55) and non-IC/BPS samples
(mean = 414 ± 47.6; N = 100). On the other hand, urine MIF concentrations in IC/BPS
patients with Hunner lesions (IC/BPS-H) were significantly higher (approximately 5-fold;
mean MIF pg/ml = 2159 ± 435.3; N = 43) compared to non-IC/BPS samples (Fig. 1A).
When normalized to creatinine concentrations, urine MIF levels in IC/BPS-NH patients
were not significantly different from non-IC/BPS values while urine MIF levels in IC/BPSH patients were significantly increased (approximately 8-fold) compared to non-IC/BPS
(Table 2A; Fig 1B).
ROC analysis showed that an optimal cut-off urine MIF level of 109.4 pg MIF/ml had a
61.8% specificity and 74.4% sensitivity in detecting IC/BPS-H vs IC/BPS-NH patients
(Figure 2A). The area under the curve (AUC) was found to be 71.8% (95% CI 61.3–82.3%).
In the case of urine MIF normalized to creatinine, ROC analysis showed that a cut-off value
of 3659 MIF pg/mg Creat had a 91% specificity and 47% sensitivity in detecting IC/BPS-H
patients (Figure 2B). The AUC was 73% (95% CI 62.2–83.1%).

Author Manuscript

MIF levels in male patients: Non-Cystitis (control group), Bacterial Cystitis and Radiation
Cystitis
Table 2B shows urine MIF levels observed in male non-cystitis samples. Patients with
bacterial cystitis had significantly elevated MIF levels in the urine, either as MIF
concentration (mean MIF pg/ml = 2839 ± 757.1; p=0.0009; Fig 1C) or normalized to
creatinine (mean MIF pg/mg Creat= 3505 ± 1028.0; p=0.0006) when compared to noncystitis samples (mean MIF pg/ml= 681 ± 75.2; MIF pg/mg Creat = 649 ± 64.5; Fig 1D).
Patients with radiation cystitis also had higher urine MIF concentrations (mean MIF pg/ml =
4404 ± 1548.1; p= 0.0001) compared to non-cystitis (Table 2B; Fig. 1C). In addition,
radiation cystitis patients had significantly increased levels of urine MIF normalized to
creatinine (mean MIF pg/mg Creat = 7360 ± 1823.0) when compared to non-cystitis patients
(Table 2B; Fig 1D).

Author Manuscript

Discussion
Based on MIF’s pro-inflammatory and pro-nociceptive roles we hypothesized that urinary
MIF would be elevated in bladder disease states marked by inflammation (and pain) such as
IC/BPS with Hunner lesions, bacterial cystitis and radiation cystitis.
Our primary aim was to measure urine MIF levels in IC/BPS patients with and without
Hunner lesions and compare them to non-IC/BPS individuals. Our findings show that urine
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MIF levels in female patients with IC/BPS and Hunner lesions are approximately five-fold
higher than urine levels in female non-IC/BPS patients or IC/BPS patients without Hunner
lesions, thus supporting our original hypothesis. Moreover, ROC analyses showed that urine
MIF levels were able to discriminate between IC/BPS patients with Hunner lesions and
those without Hunner lesions, with an urine MIF threshold value of 109.4 pg/ml achieving
62% specificity and 74% sensitivity in separating the two groups. Normalizing urine MIF
concentration to creatinine was less useful, since it had a greater sensitivity but lower
specificity than urine MIF concentration (in pg/ml). This is an interesting and potentially
clinically useful finding that needs validation in a prospective study to determine whether
urine MIF may aid IC/BPS diagnosis.

Author Manuscript

Presently it is not known whether patients with and without Hunner lesions have different
pathophysiology or mechanisms or represent two points in a continuum. Mounting evidence
indicates that they represent separate clinical conditions 16,17. From the clinician’s
perspective, identification or exclusion of these regions of focal inflammatory disease has
important treatment implications. For example, their presence might prompt an early
recommendation for an ablative procedure, while this would not be considered in other
IC/BPS patients 18,19. Furthermore, immunotherapy such as cyclosporine appears to have a
more profound clinical benefit in those patients with visible inflammation 20. Having a urine
marker to distinguish these groups has the potential to direct care more effectively and may
obviate the need for more invasive procedures.

Author Manuscript

Previously it was assumed that Hunner lesions were rare, but modern evidence suggests a
much higher prevalence 21. Detection of Hunner lesions depends on attention and training.
Therefore, non-invasive methods other than cystoscopy, are needed to increase the detection
rate. Determination of intravesical evaporation of nitric oxide (NO) is one non-cystoscopic
method to differentiate the classic Hunner type from other IC/BPS presentations 22. This
method is easy and simple to use but a disadvantage is that a special device is required; so
far it is not generally used. Another potential biomarker (etiocholan-3α-ol-17-one sulfate)
has been recently reported as being able to identify IC/BPS patients 23. Unfortunately, the
use of sophisticated assay procedures currently preclude their clinical usefulness. Detection
of urine MIF would be an attractive alternative in the sense that it only requires urine
samples and instrumentation common to most facilities for analysis.

Author Manuscript

Developing non-invasive markers that may separate these two groups of IC/BPS patients is
clinically important 24. A recent study described several chemokines that were increased in
the urine of IC/BPS patients with Hunner lesions including nerve growth factor (NGF) 25.
Interestingly, experimental evidence suggests that MIF release is upstream of NGF release
after bladder injury 7. Furthermore, bladder NGF levels correlated well with pain scores in
experimental animals while MIF antagonism prevented both bladder pain and increases in
bladder NGF levels 8.
Although MIF itself was not reported as being upregulated in IC/BPS patients with Hunner
lesions, CD74 (cognate receptor for MIF 26) was indeed upregulated 16. Previous findings
showed that CD74 is upregulated and expressed in urothelial cells after experimental bladder
injury and MIF binds to these receptors to mediate bladder inflammation 11. Based on the
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experimental evidence, it is tempting to speculate that increased MIF urine levels in patients
with Hunner lesions would be available to bind to CD74 receptors and thus mediate bladder
inflammation and pain in these patients. Our current findings of increased urine MIF levels
in patients with Hunner lesions and published evidence of upregulated chemokines and/or
receptors that are mediated by MIF strongly indicate that MIF is a crucial component of
bladder inflammation (and pain) in this cohort of patients.

Author Manuscript

In terms of our secondary aim, our current findings in bacterial cystitis patients show that
urinary MIF is increased in this population approximately 4-fold compared to non-cystitis
values. These findings confirm and extend previous results from a much smaller data set
than the current study 12. Similarly, urine MIF levels in radiation cystitis patients were
increased approximately 6-fold over non-cystitis patients. Acute, uncomplicated bacterial
cystitis is a common occurrence in urologic practice and treatment regimens are welldelineated 27. Radiation cystitis is common side-effect of pelvic radiation for malignancies
and management of this condition is also well described 28. These two conditions result in
frank bladder inflammation and thus serve as a good test of our original hypothesis that
urine MIF levels are elevated in patients with bladder inflammation from these causes.

Author Manuscript
Author Manuscript

The current study has a number of limitations. First, we used patients without the selected
diagnoses as controls (non-IC/BPS; non-cystitis) rather than normal healthy volunteers.
Urine MIF levels in normal healthy volunteers (N=12) are reported to be in range with our
current findings 29 or lower than our findings (N=20) 30. A larger study of normal healthy
volunteers of both sexes is needed to determine a more accurate range of urine MIF
concentration in normal individuals. Second, we did not determine or control for possibly
co-morbidities that may affect urine MIF levels. Our group of IC/BPS (and bacterial cystitis)
patients was heterogeneous. Most are afflicted by a wide variety of comorbid conditions,
some of which may have an inflammatory component. Third, there is a significant age
difference in the female groups. IC/BPS patients without Hunner lesions were younger (43
± 1.9) than those with Hunner lesions (64 ± 2.0) or non-IC/BPS (54 ± 1.2). This age
difference has been observed in previous reports 17. It is unlikely that increased age in the
IC/BPS patients with Hunner lesions accounts for the increased urine MIF levels we found,
since non-IC/BPS patients were also older than IC/BPS patients without Hunner lesions and
yet their urine MIF levels were very similar. Fourth, there was no assessment of the
relationship between IC/BPS symptoms (for example, pain) and urine MIF levels. Although
all patients were symptomatic (including pain) at the time of collection, questionnaires were
not obtained in this preliminary study. Our goal was to identify specific urine changes in
MIF between the IC/BPS with Hunner lesions patients and the non-Hunner patients. Fifth, it
should be noted that two of the groups did not reach full enrollment and therefore
comparisons are likely underpowered and require a larger study. Lastly, samples were
obtained from several institutions. Possible differences between institutions were not tested
due to unequal sample sizes. For these reasons, our findings should be considered as
preliminary and awaiting validation from future studies addressing these issues.
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Conclusions
Our findings demonstrate that urine MIF is elevated in patients with bladder inflammatory
conditions, supporting our original hypothesis. Our findings of a difference in urine MIF
levels between the two IC/BPS groups add to the growing body of evidence that these
patients may represent different disease entities and/or etiologies 16,17. In addition, this
difference raises the possibility that urine MIF may have diagnostic value in separating the
clinical presentation of these two groups.
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Figure 1.

Urine MIF levels in all patient groups. A: Urine MIF concentration (pg/ml) in non-IC/BPS
patients (control group) and IC/BPS patients with (IC/BPS-H) and without (IC/BPS-NH)
Hunner lesions. Urine MIF was significantly elevated (#; p < 0.001) in IC/BPS-H patients.
B: Urine MIF levels normalized to creatinine (MIF pg/mg Creat). IC/BPS patients with
Hunner lesions also had significantly elevated (#; p <0.001) levels compared to non-IC/BPS
patients. C; D: Urine MIF levels, either as concentration (pg/ml; C) or MIF normalized to
creatinine (MIF pg/mg Creat) were significantly elevated (#; p < 0.001) in both patients with
bacterial and radiation cystitis when compared to non-cystitis patients.
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Figure 2.

Receiver operating curve for urine MIF concentration (pg MIF/ml; A) and urine MIF
normalized to creatinine (MIF pg/mg Creat; B). Area under the curve (AUC) presented with
confidence intervals. Most appropriate cut-off point displayed along with sensitivity and
specificity.
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